{
    "2018-04-08": [
        [
            {
                "time": "2018-04-03",
                "original_text": "[强于大市评级]医药行业政策点评：国务院发布仿制药框架政策 看好国内优质药企进口替代及行业集中度提升机会",
                "features": {
                    "keywords": [
                        "仿制药",
                        "框架政策",
                        "进口替代",
                        "行业集中度"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-04-05",
                "original_text": "[强于大市评级]医药生物行业点评：国务院出台鼓励仿制药文件 国产仿制药迎来春天",
                "features": {
                    "keywords": [
                        "仿制药",
                        "国产",
                        "春天"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-04-06",
                "original_text": "免疫疗法点燃抗癌新希望 6股获机构扎堆推荐",
                "features": {
                    "keywords": [
                        "免疫疗法",
                        "抗癌",
                        "机构推荐"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-04-07",
                "original_text": "[推荐评级]医药行业重点公司2018年一季报业绩前瞻：聚焦一季报 关注创新+升级主线",
                "features": {
                    "keywords": [
                        "一季报",
                        "创新",
                        "升级"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-08",
                "original_text": "[看好评级]医药行业事件点评：国务院仿制药政策点评：从仿制药大国走向仿制药强国",
                "features": {
                    "keywords": [
                        "仿制药",
                        "政策",
                        "强国"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-04-09",
                "original_text": "[推荐评级]医药行业2018年4月份投资月报暨Q2季度策略：创新+升级 从初春到盛夏",
                "features": {
                    "keywords": [
                        "创新",
                        "升级",
                        "Q2策略"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "生物医药行业:《关于改革完善仿制药供应保障及使用政策的意见》出台,国内优质仿制药企业受益",
                "features": {
                    "keywords": [
                        "仿制药",
                        "政策",
                        "优质企业"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false"
                }
            }
        ]
    ]
}